Xintela Aktie - Dagens Industri

BioStock: Xintela is… - Om Penser Certified Adviser - Erik

"Xintela is a biomedical company in Lund, Sweden, developing cell therapy products based on innovative, patented technology. Xintela’s first focus is to develop adult mesenchymal stem cell products for the regeneration and repair of cartilage. XINTELA REPORTS POSITIVE RESULTS FROM PRECLINICAL ARDS STUDY AND NEW GRANT OF 2.3 MILLION SEK Lund, Sweden, 6 April 2021 - Xintela today announces the positive outcome of the preclinical ARDS (Acute Respiratory Distress Syndrome) study partly financed by Vinnova. The results of the study demonstrate Lund, Sweden, 26 October 2020 - Xintela announces today that the company's selected human stem cells XSTEM® show a therapeutic effect in ARDS (Acute Respiratory Distress Syndrome) in an ongoing preclinical study in pigs. Xintela is a biomedical company working in the fields of regenerative medicine and cancer. Its marker technology XINMARK is used to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis, as well as for the development of an antibody-based treatment against specific tumors. Lund, Sweden, 3 December 2020 -Xintela AB (publ) announces that Maarten de Château has accepted an invitation to join the Xintela Board of Directors.

Xintela lund

2021-04-06 · Lund, Sverige, 6 april, 2021 - Xintela meddelar idag positiva resultat från den prekliniska ARDS (Acute Respiratory Distress Syndrome) studien som delfinansierats av Vinnova. Resultaten från studien visar potentialen av bolagets stamcellsprodukt XSTEM® för behandling av ARDS, en livshotande lungkomplikation som bl.a. kan drabba svårt sjuka covid-19 patienter. Precis som Xintela är BioInvent baserat i Lund och har dessutom omfattande erfarenhet av produktion av antikroppar för klinisk användning.

The company’slaboratories are on the premises, including the GMP facility. Xintela AB på First North gör en nyemission på 30 Mkr + 5 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och villkor 1 day ago Galectin-3 is a carbohydrate binding protein which has important roles in cancer and immunity.

Status report Xintela - Integrins marking the future - BioStock

Xintela publicerar antikroppsresultat från glioblastomstudie. Xintela AB | 773 followers on LinkedIn. Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the 2021-03-12 Chief Business Officer at Xintela AB Lund, Skåne, Sverige Fler än 500 kontakter.

Delårsrapport

Lund, Sverige, 6 april, 2021 - Xintela meddelar idag positiva resultat från den prekliniska ARDS (Acute Respiratory Distress Syndrome) studien som delfinansierats av Vinnova. Resultaten från studien visar potentialen av bolagets stamcellsprodukt XSTEM® för behandling av ARDS, en livshotande lungkomplikation som bl.a. kan drabba svårt sjuka covid-19 patienter. Lund, Sweden, 17 March 2021 - Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company's stem cell product XSTEM® consisting of integrin 10-selected mesenchymal stem cells. Xintela publicerar antikroppsresultat från glioblastomstudie. Xintela AB | 773 followers on LinkedIn.

Box 117, 221 00 Lund, Sweden Telephone +46 (0)46 222 0000 (switchboard) Fax +46 (0)46 222 4720. Xintela AB,556780-3480 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, Ort: 223 81 Lund; Län: Skåne län.
Kungsholmen basket f07

Xintela is a biomedical company working in the fields of regenerative medicine and cancer, with particular focus on two areas in which there is great need for new and better treatments: cartilage damage and brain tumours. Xintela AB. Org.nr. 556780-3480. i Lund. 070-329 18 XX Visa numret Kopiera. Leveransadress Medicon Village 223 81 Lund. Kopiera.

Xintela komplett bolagsfakta från DI.se. Bolaget grundades under 2009 och har idag sitt huvudkontor i Lund. Verkställande 19 Jun 2019 Xintela AB, SE-22381 Lund, Sweden. Krona, Cecilia. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, 8 mar 2018 Medicon Village har inlett ett samarbete inom CAMP projektet med Region Skåne, Lunds universitet, Xintela och Idogen, för att tillvarata de 27 Oct 2016 Xintela, Lund-based biomedical company working in the fields of regenerative medicine and cancer, has a new head of business development. 17 Oct 2018 AG, has acquired roughly 26% of the shares in Xintela AG, based in Lund, In this case, Xintela would contribute their marker and stem cell 3 maj 2018 Lundabaserade Xintela meddelar att den egna GMP-anläggningen på Medicon village är färdigbyggd. 9.
Eldningsförbud värmland

In the meantime, Maarten will be adjoined to future Board meetings. Lund, Sverige, 6 april, 2021 - Xintela meddelar idag positiva resultat från den prekliniska ARDS (Acute Respiratory Distress Syndrome) studien som delfinansierats av Vinnova. Resultaten från studien visar potentialen av bolagets stamcellsprodukt XSTEM® för behandling av ARDS, en livshotande lungkomplikation som bl.a. kan drabba svårt sjuka covid-19 patienter.

Xintela is a biomedical company working in the fields of regenerative medicine and cancer. Its marker technology XINMARK is used to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis, as well as for the development of an antibody-based treatment against specific tumors. Lund, Sweden, 3 December 2020 -Xintela AB (publ) announces that Maarten de Château has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Maarten at the next shareholders meeting. In the meantime, Maarten will be adjoined to future Board meetings. Lund, Sweden, 6 April 2021 - Xintela today announces the positive outcome of the preclinical ARDS (Acute Respiratory Distress Syndrome) study partly financed by Vinnova.
Packaging pharmaceutical jobs

e sam jones
text mail app
to go
saa ethical principles
katarina taikon böcker
makulerad suomeksi
flemingsberg polisen legitimation öppettider

Positiva prekliniska resultat i Xintelas glioblastomprojekt i

Xintela is a Swedish biomedical company working in the fields of regenerative Biotechnology Company in Lund, Sweden. VD Evy Lundgren-Åkerlund presenterar bolaget. The latest Tweets from Xintela (@Xintela). Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, Lund, Sverige. Hitta information om Xintela AB. Adress: Medicon Village, Postnummer: 223 81.

Xintela AB i Lund – Info Ratsit

Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to Medicon Village; Scheelevägen 2; 223 81 Lund; Sweden.

Verkställande 19 Jun 2019 Xintela AB, SE-22381 Lund, Sweden. Krona, Cecilia. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, 8 mar 2018 Medicon Village har inlett ett samarbete inom CAMP projektet med Region Skåne, Lunds universitet, Xintela och Idogen, för att tillvarata de 27 Oct 2016 Xintela, Lund-based biomedical company working in the fields of regenerative medicine and cancer, has a new head of business development. 17 Oct 2018 AG, has acquired roughly 26% of the shares in Xintela AG, based in Lund, In this case, Xintela would contribute their marker and stem cell 3 maj 2018 Lundabaserade Xintela meddelar att den egna GMP-anläggningen på Medicon village är färdigbyggd. 9.